1. Home
  2. CRBP vs VWAV Comparison

CRBP vs VWAV Comparison

Compare CRBP & VWAV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Corbus Pharmaceuticals Holdings Inc.

CRBP

Corbus Pharmaceuticals Holdings Inc.

HOLD

Current Price

$10.10

Market Cap

147.4M

Sector

Health Care

ML Signal

HOLD

VWAV

VisionWave Holdings Inc.

HOLD

Current Price

$5.65

Market Cap

148.1M

Sector

Technology

ML Signal

HOLD

Company Overview

Basic Information
Metric
CRBP
VWAV
Founded
2009
2024
Country
United States
United States
Employees
N/A
12
Industry
Biotechnology: Pharmaceutical Preparations
Computer Software: Prepackaged Software
Sector
Health Care
Technology
Exchange
Nasdaq
Nasdaq
Market Cap
147.4M
148.1M
IPO Year
2014
N/A

Fundamental Metrics

Financial Performance
Metric
CRBP
VWAV
Price
$10.10
$5.65
Analyst Decision
Strong Buy
Analyst Count
5
0
Target Price
$45.60
N/A
AVG Volume (30 Days)
201.7K
392.1K
Earning Date
05-05-2026
05-18-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$4,822,272.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
$100.00
N/A
P/E Ratio
N/A
N/A
Revenue Growth
97.62
N/A
52 Week Low
$4.64
$2.06
52 Week High
$20.56
$15.80

Technical Indicators

Market Signals
Indicator
CRBP
VWAV
Relative Strength Index (RSI) 62.24 40.03
Support Level $9.86 N/A
Resistance Level $11.64 $8.41
Average True Range (ATR) 0.69 0.85
MACD 0.09 -0.09
Stochastic Oscillator 83.54 30.35

Price Performance

Historical Comparison
CRBP
VWAV

About CRBP Corbus Pharmaceuticals Holdings Inc.

Corbus Pharmaceuticals Holdings Inc is a clinical stage company focused on new therapies in oncology and obesity and is committed to helping people defeat serious illness by bringing inventive scientific approaches to well-understood biological pathways. The company's development pipeline includes; CRB-701, a next-generation antibody-drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload, CRB-601, an anti-integrin monoclonal antibody that blocks the activation of TGF expressed on cancer cells, and CRB-913 a second-generation peripherally restricted CB1 receptor inverse agonist designed to treat obesity.

About VWAV VisionWave Holdings Inc.

VisionWave Holdings Inc is a technology company focused on the development and commercialization of artificial intelligence (AI) and autonomous solutions across air, ground and sea environments. Through its subsidiary, the Company designs and deploys technologies including radars, radio frequency (RF) sensing, unmanned aerial and ground systems, remote weapon stations and active protection systems for defense, military, homeland security and industrial applications. Its proprietary AI engine supports autonomous decision-making and product lines at various stages of development and commercialization. Revenue is generated through product sales, technology licensing, strategic alliances and joint ventures, with products including C-UAS, multi-purpose autonomous UAS and Vision-AI technology.

Share on Social Networks: